JP2010505818A - 甲殻類の胃石成分を含む組成物とその使用 - Google Patents

甲殻類の胃石成分を含む組成物とその使用 Download PDF

Info

Publication number
JP2010505818A
JP2010505818A JP2009531012A JP2009531012A JP2010505818A JP 2010505818 A JP2010505818 A JP 2010505818A JP 2009531012 A JP2009531012 A JP 2009531012A JP 2009531012 A JP2009531012 A JP 2009531012A JP 2010505818 A JP2010505818 A JP 2010505818A
Authority
JP
Japan
Prior art keywords
caco
chitin
composition
ratio
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009531012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505818A5 (enExample
Inventor
ベン、ヨッシー
サギ、アミル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2010505818A publication Critical patent/JP2010505818A/ja
Publication of JP2010505818A5 publication Critical patent/JP2010505818A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
JP2009531012A 2006-10-05 2007-10-07 甲殻類の胃石成分を含む組成物とその使用 Pending JP2010505818A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
PCT/IL2007/001211 WO2008041236A2 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components, calcium carbonate and its use

Publications (2)

Publication Number Publication Date
JP2010505818A true JP2010505818A (ja) 2010-02-25
JP2010505818A5 JP2010505818A5 (enExample) 2010-11-18

Family

ID=39153987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531012A Pending JP2010505818A (ja) 2006-10-05 2007-10-07 甲殻類の胃石成分を含む組成物とその使用

Country Status (14)

Country Link
US (2) US20100098774A1 (enExample)
EP (1) EP2068891B1 (enExample)
JP (1) JP2010505818A (enExample)
CN (1) CN101563091A (enExample)
AU (1) AU2007303786B2 (enExample)
CA (1) CA2665141C (enExample)
CY (1) CY1114930T1 (enExample)
DK (1) DK2068891T3 (enExample)
ES (1) ES2439741T3 (enExample)
IL (1) IL178495A (enExample)
PL (1) PL2068891T3 (enExample)
PT (1) PT2068891E (enExample)
SI (1) SI2068891T1 (enExample)
WO (1) WO2008041236A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516930A (ja) * 2015-06-04 2018-06-28 アモーフィカル リミテッド． ポリリン酸塩又はビスホスホネートで安定化した非晶質炭酸カルシウム
JP2019501947A (ja) * 2016-01-18 2019-01-24 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
KR20190073448A (ko) * 2016-10-25 2019-06-26 아모피컬 리미티드 백혈병 치료용 비결정성 탄산칼슘

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257750B2 (en) * 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
CN101969962B (zh) 2007-10-22 2014-10-22 艾玛菲克有限公司 包含磷酸化氨基酸、合成的磷酸化肽和胃石蛋白的稳定的无定形碳酸钙
CA3056570C (en) * 2011-12-13 2022-04-19 Amir Sagi Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
RU2637019C2 (ru) 2012-08-07 2017-11-29 Аморфикал Лтд. Способ получения стабилизированного аморфного карбоната кальция
CN105007925A (zh) * 2013-02-11 2015-10-28 艾玛菲克有限公司 用于加速骨生长的无定形碳酸钙
CN103417635B (zh) * 2013-08-15 2015-05-20 张荣惠 接骨药
RU2740453C2 (ru) 2014-07-31 2021-01-14 Аморфикал Лтд. Неводные жидкие и полутвердые составы аморфного карбоната кальция
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
BR122022001962B1 (pt) * 2015-12-14 2023-05-16 Société des Produits Nestlé S.A. Composição nutricional sintética, seu uso, e derivado de ácido graxo
US11478011B2 (en) 2015-12-14 2022-10-25 Societe Des Produits Nestle S.A. Nutritional compositions and infant formula for promoting de novo myealination
EP4233907A3 (en) * 2015-12-14 2024-01-10 Société des Produits Nestlé S.A. Nutritional compositions and infant formulas to promote myelination in the brain
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
CA3144221A1 (en) 2019-07-23 2021-01-28 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115414A2 (en) * 2004-05-26 2005-12-08 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) * 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US20030077604A1 (en) * 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) * 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
JP2005501845A (ja) * 2001-08-16 2005-01-20 メディカル リサーチ カウンシル キチン微小粒子およびそれらの医学的用途
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
AU2003271016A1 (en) * 2003-09-17 2005-04-06 Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
WO2005115414A2 (en) * 2004-05-26 2005-12-08 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516930A (ja) * 2015-06-04 2018-06-28 アモーフィカル リミテッド． ポリリン酸塩又はビスホスホネートで安定化した非晶質炭酸カルシウム
JP7007716B2 (ja) 2015-06-04 2022-01-25 アモーフィカル リミテッド． ポリリン酸塩又はビスホスホネートで安定化した非晶質炭酸カルシウム
JP2019501947A (ja) * 2016-01-18 2019-01-24 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
JP2021105026A (ja) * 2016-01-18 2021-07-26 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
JP7190760B2 (ja) 2016-01-18 2022-12-16 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
JP2023029914A (ja) * 2016-01-18 2023-03-07 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
JP7507506B2 (ja) 2016-01-18 2024-06-28 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
KR20190073448A (ko) * 2016-10-25 2019-06-26 아모피컬 리미티드 백혈병 치료용 비결정성 탄산칼슘
JP2019532086A (ja) * 2016-10-25 2019-11-07 アモーフィカル リミテッド． 白血病治療のための非晶質炭酸カルシウム
JP7152785B2 (ja) 2016-10-25 2022-10-13 アモーフィカル リミテッド． 白血病治療のための非晶質炭酸カルシウム
KR102531595B1 (ko) * 2016-10-25 2023-05-11 아모피컬 리미티드 백혈병 치료용 비결정성 탄산칼슘

Also Published As

Publication number Publication date
ES2439741T3 (es) 2014-01-24
US20130122117A1 (en) 2013-05-16
DK2068891T3 (da) 2014-01-13
IL178495A (en) 2014-12-31
CN101563091A (zh) 2009-10-21
PL2068891T3 (pl) 2014-03-31
US20100098774A1 (en) 2010-04-22
CA2665141A1 (en) 2008-04-10
CA2665141C (en) 2015-03-24
CY1114930T1 (el) 2016-12-14
WO2008041236A3 (en) 2009-05-14
EP2068891B1 (en) 2013-09-25
EP2068891A2 (en) 2009-06-17
PT2068891E (pt) 2013-12-27
AU2007303786B2 (en) 2012-07-26
WO2008041236A2 (en) 2008-04-10
AU2007303786A1 (en) 2008-04-10
IL178495A0 (en) 2007-02-11
SI2068891T1 (sl) 2014-02-28
US8728533B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
US8728533B2 (en) Composition comprising crustacean gastrolith components and its use
CN101720939B (zh) 一种大鲵肉骨粉胶囊、制备方法及其用途
KR101497003B1 (ko) 인산염 흡착제
CN104188999A (zh) 一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法
CN104116022B (zh) 用于改善妇女更年期综合症的复合保健食品及其制备方法
CN1374839A (zh) 柠檬酸钙钾组合物和生产方法
CN104605226A (zh) 一种具有增加骨密度功能的保健品
CN103349674B (zh) 一种增加骨密度、防治骨质疏松症的龟甲林蛙油组合物
CN103142641B (zh) 一种碳酸钙维生素k药物制剂及其制备方法
CN101268836B (zh) 一种营养高钙冲剂及其生产制作工艺
CN1917868B (zh) 包含l-丝氨酸、l-异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物
RU2379043C2 (ru) Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
CN103877140A (zh) 雪莲培养物在制备促进骨骼健康产品中的应用
CN103006693A (zh) 一种二维碳酸钙组合物
CN103142568B (zh) 一种醋酸钙维生素k药物制剂及其制备方法
JP3248170B2 (ja) コンドロイチン硫酸蛋白複合体含有食品
WO2008123970A1 (en) Herbal formulation for the treatment of bone fractures and osseous defects
CN104587456A (zh) 一种增加骨密度的保健品的制作工艺
CN103040844A (zh) 一种二维醋酸钙组合物
HU200933B (en) Process for producing pharmaceutical composition for profilacting and treating osteoporosis
CN110384241A (zh) 一组有助于骨健康的组合物及其制备方法
CN117064912A (zh) 一种矿物离子组合物及其在制备对痛症具有治疗作用的产品中的应用
ES2489540T3 (es) Uso de zeolita natural en la terapia y profilaxis de la osteoporosis
CN108126013A (zh) 一种健脾促进钙吸收的缓释中药及其制备方法和药粥
JP2010159216A (ja) 鎮痛剤及び鎮痛システム

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130524